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Mycosis fungoides (MF) is a form of cutaneous T cell lymphoma deﬁned by epidermotropism of a clonal T
helper memory/effector subset. Erythrodermic MF usually presents a chronic course of MF with gener-
alized erythema or poikiloderma but no systemic involvement, as in Sezary syndrome. Here we report a
case of a 73-year-old Taiwanese male with a rapid progression of erythrodermic MF within 1.5 years. It
was diagnosed after his ﬁfth skin biopsy, which demonstrated a positive clonal band in the T cell receptor
Db-Jb and Vgf1-Jg gene. The sequential skin manifestations were eczema and contact dermatitiselike
well-deﬁned skin lesions over the back with the pathological characters of interface dermatitis and
psoriasiform dermatitis, respectively. He was treated with oral bexarotene (prescribed in the United
States) but found the side effects intolerable. We administered low-dose methotrexate (MTX, 7.5e15 mg/
wk) and 311 nm UV-B for the erythrodermic MF. After 3 years of treatment, the skin lesions completely
subsided, and a skin biopsy showed no more clonal T cells. Flow cytometry analysis revealed the decline
of the HLA-DRþ T helper cell ratio in peripheral blood during MTX administration and parallel with the
cutaneous improvement. Inhibition of histone deacetylase activity has been identiﬁed to be a novel
function of MTX. We propose that MTX can be an effective and safe treatment for erythrodermic MF. The
mechanisms of MTX in cutaneous T cell lymphoma, especially the role of immunomodulation and his-
tone deacetylase inhibition, are reviewed.
Copyright © 2015, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Mycosis fungoides (MF) is the most common type of cutaneous T
cell lymphoma (CTCL). It is deﬁned by the cutaneous presentation
and accumulation of a T helper memory/effector subset with a
CD4þ, CD8e, CD45ROþCLAþ phenotype.1 Early MF is characterized
by eczematous or psoriasiform dermatitis limited to less than 10%
of the body surface. MF may progress to a leukemic and eryth-
rodermic condition called Sezary syndrome, which requires they have no ﬁnancial or non-
atter or materials discussed
gy, Kaohsiung Medical Uni-
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Chang).
al Association. Published by Elsevipresence of >1000/mL of atypical circulating cells and usually
evolves through an indolent and chronic course.2
The ﬁrst therapy frequently used before MF is diagnosed is the
application of topical corticosteroids of increasing potency. For
early MF (<10% involvement, IA), topical 1% bexarotene gel (the
only topical therapy approved for MF) shows a 76% response rate.3
The topical inducer of interferon, imiquimod 5%, has produced 50%
histological clearing of MF when applied three times per week for
12 weeks.4 Lesions in sun-shielded areas fade with exposure to UV-
B or UV-A light. For refractory early MF (no response to topical
therapies) or intermediate MF (>10% skin involvement, IB, or with
dermopathic nodes, IIA), patch lesions can be treated with
narrowband (NB; 311 nm) UV-B combined with topical therapies;
thick plaque or folliculotropic lesions may need PUVA plus inter-
feron or oral retinoid. Oral bexarotene has received U.S. Food and
Drug Administration (FDA) approval for treatment of the cutaneouser Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Y.-H. Kuo, C.-H. Chang / Dermatologica Sinica 34 (2016) 37e4138manifestations of CTCL, along with interferon alpha. Bexarotene
monotherapy has a response rate of 54% at a dose of 300 mg/m2.5
Denileukin diftitox, a fusion protein composed of interleukin-2
and diphtheria toxin, has received FDA approval for all stages of
CTCL, showing a response rate of 30%.6 Extracorporeal photo-
pheresis was approved in 1987 for the treatment of CTCL, and
signiﬁcant response has been seen in erythrodermic patients.7
Patients with transformed MF, tumors, or nodal disease may
respond to local irradiation, denileukin diftitox, or combined
chemotherapy. Various chemotherapy combinations, while effec-
tive for a limited time, can also induce further immunosuppression,
leading to sepsis or opportunistic infections. Total electron beam
irradiation is reserved for patients who have extensive skin
involvement and have failed to respond to skin-directed therapies.
Methotrexate (MTX) is an antimetabolite and antifolate agent
that is used in many interventions, especially in cancer treatment
and immunomodulation, but has not been accepted as a standard
treatment for MF. Wright et al8 were the ﬁrst to propose, in 1984,
treating MF patients with MTX. Zackheim et al9 reported a case
series (29 patients) of erythrodermic MF treated with low-dose
methotrexate with a complete remission rate of 41% and a total
response rate of 58%. In another retrospective study, conducted in
2003, 60 of the 69 MF patients treated with low-dose MTX had
patch/plaque-stage T2 disease with a 12% complete remission rateFigure 1 (A) Initial presentation at ﬁrst visit with itching erythematous papules and conﬂ
psoriasis-like erythroderma despite treatment with topical betamethasone dipropionate;
lymphocytes (hematoxylineeosin stain, 100).and 33% total response rate.10 No similar case series studies have
been done among Asian patients.
Here we present a 3-year follow-up study of an individual with
erythrodermic MF who was well-treated with low-dose MTX and
311 nmUV-B. The novel function ofMTX in the immunomodulation
and inhibition of histone deacetylase (HDAC) is discussed.
Case Report
A 73-year-old Taiwanese male ﬁrst visited the Department of
Dermatology of Kaohsiung Medical University Hospital presenting
with itching erythematous papules starting from the lower back
and gradually spreading to the entire trunk (Figure 1A). The ﬁrst
skin biopsy (Figure 1C) showed only mild interface dermatitis with
superﬁcial perivascular inﬁltrations. Therefore, the diagnosis was
contact dermatitis with generalized eczema, and the patient was
treated with topical betamethasone dipropionate ointment.
Despite treatment, the lesions worsened to psoriasis-like eryth-
roderma (Figure 1B) within 8 months. A second skin biopsy was
performed, but it still showed interface dermatitis without any
evidence of atypical lymphocytic inﬁltrations (Figure 1D). The pa-
tient was given topical and oral steroids, with limited improve-
ment. He later visited the Department of Dermatology of
Pennsylvania University (USA) and underwent another two skinuent patches; (B) eight months after ﬁrst visit, skin lesions progressed to generalized
(C,D) both skin biopsy results showed mild interface dermatitis without any atypical
Figure 2 (A,B) Generalized erythroderma with poikiloderma and reticular-patterned erythematous plaques was noted 20 months after ﬁrst visit; (C) acanthosis of epidermis with a
dense inﬂammatory band at the dermaleepidermal junction (hematoxylineeosin stain,100); (D) epidermotropism of atypical lymphocytes noted in the circles (hematox-
ylineeosin stain, 400); the atypical lymphocytes were (E) CD4þ (40) and (F) CD8e (40) cells; (G) most of the atypical lymphocytes express CD5 (40); (H) increased staining of
Ki-67 over basal layer (40).
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suspicion of mycosis fungoides, the patient was treated with oral
bexarotene there, but he could not tolerate the side effects,
including a severe sensation of nausea and elevated liver functions.
The skin lesions still progressed despite all efforts.
He visited us again 20 months after the ﬁrst visit and presented
with generalized erythroderma with poikiloderma and reticular-
patterned erythematous plaques (Figure 2A, Figure 2B). No
lymphadenopathy was noted during thorough palpation. A ﬁfth
skin biopsy was performed, and it revealed the inﬁltration of
atypical lymphocytes into the dermis and epidermis (Figure 2C,
Figure 2D). Immunophenotyping by CD markers, including CD3,
CD4, CD8, CD5, and CD20, showed the atypical lymphocytes in the
epidermis and dermisweremainly positive for CD3 but negative for
CD20, indicating a T cell population. The atypical lymphocytes were
positive for CD4 (Figure 2E) but negative for CD8 (Figure 2F),
indicating T helper cells. These cells mostly express CD5
(Figure 2G). Because of epidermal hyperplasia, we performed pro-
liferation marker Ki-67 staining, which showed increased Ki-67
expression in the basal layer of the epidermis (Figure 2H). Anal-
ysis of the rearrangement of T cell receptor genes revealed aFigure 3 Marked improvement in erythroderma and poikiloderma after treatment with low
MTX accumulative dose was also calculated. (A) Before treatment; (B) treatment for 1 year; (
postinﬂammatory hyperpigmentation; (D) MTX dosage in the entire 30 months of treatme
much improvement in skin condition, we started to taper MTX dosage at 22 months. (E) Pe
suppressed by MTX. MTX ¼ methotrexate.positive clonal band in the T cell receptor Db-Jb and Vgf1-Jg gene
(multiplex polymerase chain reaction). Erythrodermic MF was
therefore diagnosed. Peripheral blood smears failed to reveal any
Sezary cells. A positron emission tomographyecomputed tomog-
raphy scan showed no evidence of internal-organ involvement. The
patient was staged as T4N0M0 (Stage III), according to the TNM
staging system of the International Society of Cutaneous Lym-
phoma and the European Organization of Research and Treatment
of Cancer.11 Low-dose oral MTX (7.5 mg per week initially with a
gradual increase to 15 mg per week) accompanied by folic acid
supplements plus NB UV-B (311 nm) phototherapy (a gradual in-
crease to 950 mJ/cm2 for three sessions per week) was adminis-
tered for treatment. During the treatment course, the patient
tolerated the therapies well, and periodic laboratory monitoring
showed no evidence of hematological, renal, or hepatic toxicity.
During follow up, the erythrodermic and poikilodermic lesions
improved month by month with no ﬂare-up of new lesions. The
reticular-patterned plaques also subsided, and postinﬂammatory
hyperpigmentation remained (Figures 3Ae3C). A follow-up skin
biopsy showed no inﬁltration of atypical lymphocytes in the
epidermis and dermis. Low-dose MTX was kept for a total of 30-dose methotrexate and 311 nm UV-B. The indurated plaques also ﬂattened. The total
C) treatment for 2 yearsdnearly total ﬂattening of the erythematous plaques except for
nt (represented as weekly dosage for 30 months, starting from 7.5 mg/wk). Because of
ripheral-blood ﬂow cytometry results showing the HLA-DRþ/CD3þ subset is sensitively
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cytometry analysis of peripheral blood demonstrated the HLA-DRþ
T helper subset (the activated lymphocytes) was sensitively
downregulated by MTX, in parallel with the improvement of the
skin lesions (Figure 3E).
Discussion
Here we present the case of an individual with erythrodermic MF
who was refractory to oral bexarotene and standard topical thera-
pies but achieved complete remission after low-dose MTX plus
311 nm UV-B for 3 years.
MTX, a structural analog of folic acid and an inhibitor of dihy-
drofolate reductase, is awidely used and highly successful anticancer
agent, such as for squamous-cell carcinoma, and immunomodulator,
such as for psoriasis.
MTX exerts immunoregulation in psoriasis by selective deletion
of activated peripheral blood T cells12 and dose-dependent sup-
pression of T cell activation and suppression of the skin-homing
cutaneous lymphocyte-associated antigen.13 Because of failure of
standard treatment and psoriasiform pathological character, we
administered MTX to the erythrodermic MF patient. Flow cytom-
etry of peripheral blood before and after MTX treatment showed
the most dramatic change of cell fraction occurred in the HLA-DRþ/
CD3þ population, which represented the activated T cells. The
decline of activated T lymphocytes in peripheral blood was also
quite parallel with the improvement of skin manifestations. MTX-
induced reduction of the activated T cell population has also been
previously reported in psoriasis. In mycosis fungoides, these acti-
vated T cells may play a role in the erythrodermic change of skin via
endothelial cell activation and keratinocyte proliferation. Tan et al
ﬁrst hypothesized that MF is a disease caused by the persistence of
chronic antigen stimulation,14 which may come from autoantigens
or environmental factors, such as Staphylococcus aureus, human T
lymphotropic virus (type 1), and EpsteineBarr virus.15 Pautrier's
microabscess is formed by atypical CD4þ lymphocytes clustering
around epidermal Langerhans cells, which activate T cells through
direct contact and provide a stimulus for their clonal expansion by
migrating to the dermis.16 Our case study ﬁrst reveals low-dose
MTX suppresses T lymphocyte activation in peripheral blood in
MF, and this immune regulatory effect signiﬁcantly improves
erythroderma, poikiloderma, and reticular-patterned (implying
dermal vessel involvement) skin lesions. Therefore, we propose
that in erythrodermic MF, especially with rapid progression in
clinical course, activation of lymphocytes in skin and blood may
play a major role in the pathogenesis, and MTX is an efﬁcient and
safe treatment for the suppression of those cells. NB UV-B irradia-
tion has also induced Tcell apoptosis in previous psoriasis studies.17
MTX exerts at least four mechanisms in anticancer agents: (1)
MTX ceases intracellular metabolism and ﬁnally blocks the syn-
thesis of thymine and purine, leading to cell cycle arrest at the S-
phase and the impairment of tumor growth; (2) MTX increases the
Fas death receptor, inducing Fas-mediated apoptosis in CTCL by
acting as a FAS promoter methylation inhibitor;18 (3) MTX pro-
motes p53 phosphorylation at Ser15 and acetylation at Lys373/382,
which increase its stability and initiate p53-dependent apoptosis;19
and (4) MTX can inhibit HDAC, which is usually overexpressed in
tumors. Therefore, MTX is a potential HDAC inhibitor.20 The average
weekly dosage of the previous case series was 25 mg (5e125 mg)
with a median of 23 months (2e129) of treatment duration,9,10
relatively higher than the dosage of our patient (7.5e15 mg
weekly for 30 months). Because our patient had no systemic
involvement and atypical lymphocytes inﬁltrated mainly into the
upper dermis, we chose NB UV-B for adjuvant ﬁeld therapy.HDAC inhibitors are a new class of antineoplastic agents that can
also be considered as biological-response modiﬁers as they
modulate the transcription of multiple genes and pathways. Vor-
inostat was approved by the U.S. FDA in 2006 for the treatment of
CTCL patients who have progressive, persistent, or recurrent dis-
ease on or following two systemic treatments. HDAC inhibitors can
induce cell cycle arrest, differentiation, and apoptosis inMF / Sezary
syndrome cell lines or in patients' peripheral blood lymphocytes.21
In our case, atypical lymphocytes in skin disappeared after MTX
and the synergistic effects of NB UV-B treatment. The novel func-
tion of MTX as an HDAC inhibitor may play a role in the eradication
of neoplastic T cells in skin. Further case studies of using MTX on
CTCL and comparative studies between MTX and vorinostat on
CTCL may provide valuable data to establish guidelines for clinical
use.
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